West Pharmaceutical Services Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.27%.
Did WST Beat Earnings? Q2 2025 Results
West Pharmaceutical Services delivered a blowout second quarter, posting adjusted diluted EPS of $1.84, beating the $1.51 consensus estimate by 21.85%, while revenue climbed 9.2% year-over-year to $766.50 million. The standout driver was accelerating demand for High-Value Product components, which powered a 290 basis point expansion in consolidated gross profit margin to 35.7%, as higher-margin products made up a growing share of the mix. HVP Components, representing 47% of total company sales, grew 11.3%, fueled by surging GLP-1 elastomer demand and 370 active Annex 1 regulatory compliance conversion projects, while HVP Delivery Devices surged 30.0%. The strong results sent shares sharply higher, with the stock on track for one of its best single-day performances in recent memory. Management responded with a meaningful guidance raise, lifting full-year 2025 revenue expectations to $3.04 billion-$3.06 billion and adjusted diluted EPS guidance to $6.65-$6.85, from prior ranges of $2.94 billion-$2.98 billion and $6.15-$6.35, respectively, buoyed in part by a roughly $59.00 million foreign exchange tailwind.
- Strong GLP-1 elastomer growth, now 8% of total company revenues
- Ongoing momentum in HVP conversion related to Annex 1 compliance projects
- Continued normalization of customer ordering patterns
- Performance concentrated in higher-margin products driving margin expansion
- Favorable foreign exchange rates providing revenue and EPS tailwinds
- HVP Delivery Devices revenue surged 30.0% driven by Crystal Zenith and Administration Systems
“I am pleased to report that we exceeded our expectations for the second quarter driven by solid growth in HVP components. This was the result of strong GLP-1 elastomer growth, ongoing momentum in HVP conversion mainly related to Annex 1 projects and the continued normalization of customer ordering patterns. The improved performance was concentrated in higher margin products, which drove strong margin expansion in the quarter. As a result of our strong second quarter performance and favorable foreign exchange, we are increasing our revenue and adjusted-diluted EPS guidance for fiscal year 2025.”
West Pharmaceutical Services CEO, on the earnings call
Forward Guidance & Outlook
West raised its full-year 2025 net sales guidance to $3.040 billion–$3.060 billion, up from $2.945 billion–$2.975 billion, with organic net sales growth expected at approximately 3.0%–3.75% (up from 2.0%–3.0%). Revenue guidance includes an estimated FX tailwind of approximately $59 million. Adjusted-diluted EPS guidance was raised to $6.65–$6.85 from $6.15–$6.35, including a $0.27 FX tailwind and $0.04 of first-half 2025 tax benefits from stock-based compensation. The company estimates $15–$20 million net impact from recently implemented tariffs, down from $20–$25 million. Full-year capital spending guidance remains at $275 million. Contract Manufacturing organic revenues are expected to increase low-single-digits for the full year. The assumed tax rate for remaining quarters is approximately 21%.
WST YoY Financials
WST Revenue by Segment
WST Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.